Buy Like Buffett
Watchlist

Flagship explainer

How BIOCRYST PHARMACEUTICALS, INC. makes its money

Start with a dollar of revenue and follow what the filing says remains.

revenueBranching filed flows with values and percentages directly labeled. Missing filing concepts are omitted rather than estimated.Revenue$875M · 100%Cost of revenue$19.1M · 2%Gross profit$856M · 98%Operating income$341M · 39%Income before tax$267M · 31%Income tax$3.5M · 0%Net income$264M · 30%As of 2025-12-31 · 1 SEC filing sourceBuy Like Buffett · buylikebuffett.com

Honest partial: the filing did not provide a normalized tag for Research and development, Selling, general and administrative; those components are omitted, not plugged.

Table alternative
Filed lineValue% of revenueSource
$875M100%
  • 10-K · FY 2025Filing detailsAccession 0001628280-26-012240 · filed Feb 26, 2026
Cost of revenue$19.1M2%
  • 10-K · FY 2025Filing detailsAccession 0001628280-26-012240 · filed Feb 26, 2026
$856M98%
  • 10-K · FY 2025Filing detailsAccession 0001628280-26-012240 · filed Feb 26, 2026
$341M39%
  • 10-K · FY 2025Filing detailsAccession 0001628280-26-012240 · filed Feb 26, 2026
Income before tax$267M31%
  • 10-K · FY 2025Filing detailsAccession 0001628280-26-012240 · filed Feb 26, 2026
Income tax$3.5M0%
  • 10-K · FY 2025Filing detailsAccession 0001628280-26-012240 · filed Feb 26, 2026
$264M30%
  • 10-K · FY 2025Filing detailsAccession 0001628280-26-012240 · filed Feb 26, 2026
Source:
  • 10-K · FY 2025Filing detailsAccession 0001628280-26-012240 · filed Feb 26, 2026
· event Dec 31, 2025 · retrieved Oct 17, 2026 · annual-row source set
Embed this chart

View the full BIOCRYST PHARMACEUTICALS, INC. analysis at Buy Like Buffett